الفهرس 
Retinal anatomyOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Abstract
Retinal vein occlusion is the second most common retinal vascular accident after diabetic retinopathy, it is caused by blood clot in the retinal vein , which slows or stops blood from leaving the retina.
Macular edema is the most common cause of persistent poor visual acuity. Ocular neovascularization is a complication of ischemic CRVO and major BRVO only. In CRVO the anterior segment is the main site of neovascularization with resultant off neovascular glaucoma ,while in BRVO the retina and the optic disc are the major sites of neovascularization.
In the ongoing armamentarium against sight threatening diseases not only the drug composition is a determining factor but also the way of delivery is a crucial point to consider. Novel methods of ophthalmic drug delivery are being developed to facilitate treatment of a variety of eye diseases.
In order to develop novel methods of ophthalmic drug delivery certain aspects should be considered.
For intraocular drug delivery, the selection of a particular system depends on the duration that is anticipated for treatment of the disease site. It is also critical to have drugs with release rate of microgram/day range, to accommodate the limited space in the human eye.
The Posurdex®; a biodegradable sustained release intravitreal implant that contains dexamethasone is mainly used in macular edema due to retinal vein occlusion, DM and uveitis.
Other sustained release implants are still under clinical trials.
KeyWords: Retinal vein occlusion- Dexamethasone- Ozurdex.